ATE399164T1 - Antagonisten des opioidrezeptors - Google Patents
Antagonisten des opioidrezeptorsInfo
- Publication number
- ATE399164T1 ATE399164T1 AT05724568T AT05724568T ATE399164T1 AT E399164 T1 ATE399164 T1 AT E399164T1 AT 05724568 T AT05724568 T AT 05724568T AT 05724568 T AT05724568 T AT 05724568T AT E399164 T1 ATE399164 T1 AT E399164T1
- Authority
- AT
- Austria
- Prior art keywords
- antagonists
- opioid receptor
- racemate
- diastereomer
- amelioration
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D313/14—[b,f]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04380057 | 2004-03-12 | ||
US55318704P | 2004-03-15 | 2004-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE399164T1 true ATE399164T1 (de) | 2008-07-15 |
Family
ID=46045513
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05724568T ATE399164T1 (de) | 2004-03-12 | 2005-03-08 | Antagonisten des opioidrezeptors |
Country Status (7)
Country | Link |
---|---|
US (1) | US7288543B2 (de) |
EP (1) | EP1730140B1 (de) |
JP (1) | JP2007528898A (de) |
AT (1) | ATE399164T1 (de) |
CA (1) | CA2558652A1 (de) |
ES (1) | ES2308471T3 (de) |
WO (1) | WO2005090337A1 (de) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2208727T1 (sl) * | 2002-09-19 | 2012-11-30 | Lilly Co Eli | Diaril etri kot antagonisti opioidnega receptorja |
DE602005012380D1 (de) | 2004-03-15 | 2009-03-05 | Lilly Co Eli | 4-(5-(aminomethyl)-indol-1-ylmethyl)benzamidderivate und verwandte verbindungen als opioidrezeptorantagonisten zur behandlung von fettleibigkeit |
CA2662766C (en) | 2006-09-08 | 2011-08-09 | Pfizer Products Inc. | Diaryl ether derivatives and uses thereof |
EP2152671A1 (de) | 2007-05-22 | 2010-02-17 | Prosidion Limited | Bicyclische aryl- und heteroarylverbindungen zur behandlung von stoffwechselerkrankungen |
EP2197835A1 (de) | 2007-09-07 | 2010-06-23 | Prosidion Limited | Bicyclische aryl- und heteroarylverbindungen als rezeptormodulatoren |
DK2252581T3 (da) * | 2008-01-22 | 2012-07-16 | Lilly Co Eli | Kappa-selektiv opioidreceptorantagonist |
AU2010295464B2 (en) * | 2009-09-18 | 2015-11-26 | Merck Sharp & Dohme Corp. | Use of opioid receptor antagonist for gastrointestinal tract disorders |
US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
AU2023232536A1 (en) | 2022-03-07 | 2024-10-24 | Janssen Pharmaceuticals, Inc. | Polymorph forms of aticaprant for use in treating major depressive disorder |
EP4489730A1 (de) | 2022-03-07 | 2025-01-15 | Janssen Pharmaceuticals, Inc. | Zusammensetzungen mit atikaprant |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4678779A (en) | 1985-01-31 | 1987-07-07 | Meyers Vera K | Weight control method |
DE4215213A1 (de) | 1992-05-09 | 1993-11-11 | Merck Patent Gmbh | Arylacetamide |
SI2208727T1 (sl) | 2002-09-19 | 2012-11-30 | Lilly Co Eli | Diaril etri kot antagonisti opioidnega receptorja |
JP2006519855A (ja) | 2003-03-07 | 2006-08-31 | イーライ リリー アンド カンパニー | オピオイド受容体アンタゴニスト |
AU2004220112A1 (en) | 2003-03-07 | 2004-09-23 | Eli Lilly And Company | 6-substituted nicotinamide derivatives as opioid receptor antagonists |
CN1890208A (zh) | 2003-12-12 | 2007-01-03 | 伊莱利利公司 | 类鸦片受体拮抗剂 |
MXPA06007198A (es) | 2003-12-22 | 2006-09-04 | Lilly Co Eli | Antagonistas de receptor opioide. |
-
2005
- 2005-03-08 US US10/598,690 patent/US7288543B2/en not_active Expired - Fee Related
- 2005-03-08 CA CA002558652A patent/CA2558652A1/en not_active Abandoned
- 2005-03-08 EP EP05724568A patent/EP1730140B1/de not_active Not-in-force
- 2005-03-08 ES ES05724568T patent/ES2308471T3/es active Active
- 2005-03-08 WO PCT/US2005/007052 patent/WO2005090337A1/en not_active Application Discontinuation
- 2005-03-08 AT AT05724568T patent/ATE399164T1/de not_active IP Right Cessation
- 2005-03-08 JP JP2007502871A patent/JP2007528898A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US7288543B2 (en) | 2007-10-30 |
EP1730140B1 (de) | 2008-06-25 |
CA2558652A1 (en) | 2005-09-29 |
US20070179129A1 (en) | 2007-08-02 |
JP2007528898A (ja) | 2007-10-18 |
EP1730140A1 (de) | 2006-12-13 |
ES2308471T3 (es) | 2008-12-01 |
WO2005090337A1 (en) | 2005-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE545413T1 (de) | Antagonisten des opioidrezeptors | |
NO20051871L (no) | Opioidreseptorantagonister | |
TW200716574A (en) | The preparation and use of compounds as aspartyl protease inhibitors | |
MX2009004900A (es) | Arilamidas sustituidas por tiazol u oxazol. | |
TW200716520A (en) | 3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | |
ECSP066640A (es) | Inhibidores heterocíclicos de aspartil proteasa | |
CA2678958C (en) | Heterocyclic aspartyl protease inhibitors | |
ATE475640T1 (de) | Antagonisten des opioidrezeptors | |
GB0225475D0 (en) | Therapeutic agents | |
WO2006098918A3 (en) | Substituted gamma lactams as therapeutic agents | |
ATE406360T1 (de) | Antagonisten der opioidrezeptoren | |
NO20071719L (no) | Pyridylinhibitorer for "hedgehog"-signalisering | |
TW200607807A (en) | Macrocyclic beta-secretase inhibitors | |
WO2007146758A3 (en) | Novel mch receptor antagonists | |
ATE446962T1 (de) | Thiazolopyridinon-derivate als mch- rezeptorantagonisten | |
ATE384058T1 (de) | Thiazolderivate | |
HRP20130614T1 (en) | Novel pyrazole-substituted arylamides | |
ATE389395T1 (de) | Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson | |
SI1828177T1 (sl) | Novi antagonisti mch receptorja | |
ATE399164T1 (de) | Antagonisten des opioidrezeptors | |
WO2006134486A3 (en) | Alpha-(aryl-or heteroaryl-methyl)-beta piperidino propanamide compounds as orl1-receptor antagonists | |
SE0401655D0 (sv) | New compounds | |
TW200621223A (en) | Acyclic 1,3-diamines and uses therefor | |
EA015500B9 (ru) | Новые антагонисты мсн рецепторов | |
TW200612912A (en) | Benzyloxy derivatives as maob inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |